Abstract
Objective: To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA. Methods: In this 12-week, double-blind period of the phase IIIb trial, RA patients with inadequate response to at least one DMARD were randomized 4:1 to CZP (400 mg at weeks 0, 2 and 4, followed by 200 mg every 2 weeks) or placebo (every 2 weeks) plus current therapy stratified by previous TNF inhibitor use, concomitant methotrexate use and disease duration (
| Original language | English (US) |
|---|---|
| Article number | kes150 |
| Pages (from-to) | 2204-2214 |
| Number of pages | 11 |
| Journal | Rheumatology |
| Volume | 51 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2012 |
Fingerprint
Keywords
- Biologicals
- Rheumatoid arthritis
- Tumour necrosis factor
ASJC Scopus subject areas
- Rheumatology
- Pharmacology (medical)
Cite this
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis : Results from the REALISTIC phase IIIb study. / Weinblatt, Michael E.; Fleischmann, Roy; Huizinga, Tom W J; Emery, Paul; Pope, Janet; Massarotti, Elena M.; van vollenhoven, Ronald F.; Wollenhaupt, Jürgen; Bingham, Clifton; Duncan, Ben; Goel, Niti; Davies, Owen R.; Dougados, Maxime.
In: Rheumatology, Vol. 51, No. 12, kes150, 12.2012, p. 2204-2214.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis
T2 - Results from the REALISTIC phase IIIb study
AU - Weinblatt, Michael E.
AU - Fleischmann, Roy
AU - Huizinga, Tom W J
AU - Emery, Paul
AU - Pope, Janet
AU - Massarotti, Elena M.
AU - van vollenhoven, Ronald F.
AU - Wollenhaupt, Jürgen
AU - Bingham, Clifton
AU - Duncan, Ben
AU - Goel, Niti
AU - Davies, Owen R.
AU - Dougados, Maxime
PY - 2012/12
Y1 - 2012/12
N2 - Objective: To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA. Methods: In this 12-week, double-blind period of the phase IIIb trial, RA patients with inadequate response to at least one DMARD were randomized 4:1 to CZP (400 mg at weeks 0, 2 and 4, followed by 200 mg every 2 weeks) or placebo (every 2 weeks) plus current therapy stratified by previous TNF inhibitor use, concomitant methotrexate use and disease duration (
AB - Objective: To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA. Methods: In this 12-week, double-blind period of the phase IIIb trial, RA patients with inadequate response to at least one DMARD were randomized 4:1 to CZP (400 mg at weeks 0, 2 and 4, followed by 200 mg every 2 weeks) or placebo (every 2 weeks) plus current therapy stratified by previous TNF inhibitor use, concomitant methotrexate use and disease duration (
KW - Biologicals
KW - Rheumatoid arthritis
KW - Tumour necrosis factor
UR - http://www.scopus.com/inward/record.url?scp=84870317631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870317631&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/kes150
DO - 10.1093/rheumatology/kes150
M3 - Article
C2 - 22923753
AN - SCOPUS:84870317631
VL - 51
SP - 2204
EP - 2214
JO - Rheumatology
JF - Rheumatology
SN - 1462-0324
IS - 12
M1 - kes150
ER -